$10.76
0.14%
Nasdaq, Sep 28, 12:20 pm EDT. Market open.
ISIN
IL0011814113
Symbol
PLRZ

Polyrizon Stock price

$10.78
-0.13 1.15% 1M
-3.46 24.28% 6M
+2.29 26.91% YTD
+4.42 69.42% 1Y
-2,314.23 99.54% 3Y
-2,314.23 99.54% 5Y
-2,314.23 99.54% 10Y
-2,314.23 99.54% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.27 2.52%
ISIN
IL0011814113
Symbol
PLRZ
Industry

Is Polyrizon a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$25.6m
Enterprise Value
$13.1m
Net debt
positive
Cash
$12.5m
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
97.9%
Return on Equity
-15.9%
ROCE
-39.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-7.9m
EBIT
$-8.3m
Net Income
$-3.5m
Free Cash Flow
$-4.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-418.3%
EBIT
-401.5%
Net Income
-57.4%
Free Cash Flow
-294.8%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-5.2
FCF per Share
$-2.8
Short interest
2.4%
Employees
3
Rev per Employee
$0.0

Financial data from Polyrizon

Dec '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.36 5.36
447% 447%
-
- Research and Development Expense 2.91 2.91
334% 334%
-
-7.93 -7.93
418% 418%
-
- Depreciation and Amortization 0.34 0.34
183% 183%
-
EBIT (Operating Income) EBIT -8.27 -8.27
402% 402%
-
Net Profit -3.51 -3.51
57% 57%
-

In millions USD.

Don't miss a Thing! We will send you all news about Polyrizon directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Polyrizon Stock News

Neutral
GlobeNewsWire
●
6 days ago
First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis Raanana, Israel, Sept.
Neutral
GlobeNewsWire
●
24 days ago
RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.
Neutral
GlobeNewsWire
●
25 days ago
RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direc...
More Polyrizon News

Company Profile

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Head office Israel
CEO Mr. Izraeli
Employees 3
Founded 2005
Website polyrizon-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today